Also found in: Medical, Encyclopedia, Wikipedia.


 (kär-bŏk′sə-lās′, -lāz′)
Any of various enzymes that catalyze the addition of a carboxyl group.


(Biochemistry) any enzyme that catalyses the release of carbon dioxide from certain acids


(kɑrˈbɒk səˌleɪs, -ˌleɪz)

any of the class of enzymes that catalyze the release of carbon dioxide from the carboxyl group of certain organic acids.
[< German (1911)]
References in periodicals archive ?
Carboxylase, protease, lipase, polymerase and xylanase are major enzyme types majorly incorporated in formulation of baked products to improve organoleptic properties and crust appearance.
The researchers discovered a novel variant of phosphoenolpyruvate carboxylase, or PEPC.
United States-based Gilead Sciences has revealed results from a Phase two, randomised, placebo-controlled trial assessing two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase intended for patients with non-alcoholic steatohepatitis (NASH), it was reported yesterday.
today announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH).
Manganese homeostasis is of great importance to the organism because it is an essential mineral for the activity of several enzymes such as pyruvate carboxylase, which catalyzes the conversion of pyruvate to oxaloacetate (16); arginase, which converts arginine to urea (17); and manganese superoxide dismutase (MnSOD), critical for antioxidant defense (18).
DRM01 is a novel topical inhibitor of acetyl coenzyme-A carboxylase, an enzyme involved in synthesis of the fatty acids that are an essential component of sebum.
Lawitz, MD, reported the promising results of a "proof of concept" open-label study in which the safety and efficacy of 12 weeks' treatment with the oral acetyl-CoA carboxylase (ACC) inhibitor, GS-0976, was examined in 10 patients with a clinical diagnosis of nonalcoholic fatty liver disease (NAFLD).
Comparative analysis of their expression levels at stage S1 and S2 showed that in both cases, acyl carrier protein (ACP) and stearoyl-ACP desaturase (SAD) were obviously up regulated (<2 fold at most), while pyruvate dehydrogenase complex (PDHC) and acetyl-CoA carboxylase (ACCase) involved in the initial synthesis exhibited much higher expression levels than those involved in elongation stage such as malonyl-CoA: ACP malonyl transferase (MCMT) and ketoacyl-ACP synthase (KAS).
Acetyl CoA carboxylase is catalyze to first phase of fatty acid biosynthesis and it synthesizes the palmitic acid.
The genes encoding levels of Acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS) and carnitine palmitoyltransferase (CPT) 1 were respectively involved in the regulation of FAS and oxidation.
Moreover, ChE treatment remarkably reduced HFD-induced high expression level of fatty acid synthesis genes (including sterolregulatory element-binding protein 1, acetyl-CoA carboxylase 1 and fatty acid synthase).